The Association of Community Cancer Centers (ACCC), Hematology/Oncology Pharmacy Association (HOPA), National
Community Oncology Dispensing Association, Inc. (NCODA), and Oncology Nursing Society (ONS) have collaborated in gathering
information for and developing this patient education guide. This guide represents a brief summary of the medication derived from
information provided by the drug manufacturer and other resources. This guide does not cover all existing information related to the
possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with this medication and should
not substitute for the advice of a qualified healthcare professional. Provision of this guide is for informational purposes only and does
not constitute or imply endorsement, recommendation, or favoring of this medication by ACCC, HOPA, NCODA, or ONS, who assume
no liability for and cannot ensure the accuracy of the information presented. The collaborators are not making any representations with
respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual
consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a
qualified healthcare professional.
Oral Chemotherapy Education (OCE) sheets are provided as a free educational resource for patients with cancer in need of
concise, easy-to-understand information about oral cancer drugs. Healthcare providers are permitted to copy and distribute the sheets to
patients as well as direct patients to the OCE website for information. However, commercial reproduction or reuse, as well as rebranding
or reposting of any type, are strictly prohibited without permission of the copyright holder. Please email permission requests and licensing
inquiries to Contact@NCODA.org.
Cookies are required to agree to our terms of service. We only use this cookie to grant access to our library.
OralChemoEdSheets.com, the Patient and Healthcare Providers Resource
Managing Hand-Foot Reaction
No Additional Resources
Hand-foot reaction (sometimes referred to as hand-foot syndrome) describes a common side effect of certain oral anticancer therapies (e.g., capecitabine, sunitinib, cabozantinib) affecting the palms of the hand and/or bottoms of the feet.
Our Supplemental Sheet
This sheet is available to download as an Adobe PDF.
This sheet is coming soon. check back later to download it as an Adobe PDF.
HAND FOOT REACTION ORAL CHEMOTHERAPY EDUCATION Hand foot reaction (sometimes referred to as hand foot syndrome) describes a common side effect of certain oral anticancer therapies (e.g., capecitabine, sunitinib, cabozantinib) affecting the palms of the hand and/or bottoms of the feet. Hand foot reaction may cause the following: Redness Tingling Numbness Swelling Cracking of the skin Thickening of the skin at pressure points (similar to calluses) Pain while on the feet or while using hands for everyday tasks Hand foot reaction typically starts after a few weeks of treatment. It will go away after treatment is stopped, but not right away. What can you do to lessen the severity of hand foot reaction? Regularly apply a moisturizing cream. • Udder Cream and Bag Balm are two commonly used products. Urea cream (10%–20%) is helpful to use on thickened skin. Wear well fitted shoes as well as socks to avoid excess rubbing on the feet. Use gloves when working with your hands. Avoid exposure to heat (including hot water) on hands and feet. Wear SPF 30 or higher daily, or wear long sleeved shirts and pants. Pat your skin dry after washing hands and feet instead of rubbing with a towel. Call your care team if you experience any of the following symptoms: You notice blistering of the hands and/or feet. You notice that it is painful to do everyday tasks with the hands and/or feet. Additional instructions